Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients

Table 6 Side effects of risperidone in follow-ups

Characteristics	Baseline	Week 4	Week 8	Differences (vs. Baseline)
Characteristics	Baseline	Week 4	Week 8	Week 4	Week 8
ESRS, n (%)		17 (25%)	20 (32.79%)
BAS, n (%)		8 (11.76%)	8 (13.11%)
Weight (Kg)	66.25 (14.06)	64.99 (13.33)	64.79 (13.37)	-1.57 (2.96)^**	-1.89 (3.42)^**
BMI	24.51 (4.49)	24.04 (4.10)	24.07 (4.14)	-0.58 (1.11)^**	-0.71 (1.27)^**
Glu (mmol/L)	5.15 (0.86)	4.90 (1.20)	5.08 (1.25)	-0.35 (1.61)	-0.23 (1.28)
TG (mmol/L)	1.62 (1.09)	1.66 (0.89)	1.67 (0.94)	0.05 (0.96)	0.01 (1.11)
CHO (mmol/L)	4.77 (0.98)	4.50 (0.96)	4.54 (0.93)	-0.28 (0.78)^*	-0.27 (0.84)^*
LDL (mmol/L)	2.24 (0.64)	2.16 (0.65)	2.16 (0.65)	-0.09 (0.55)	-0.17 (0.74)
HDL (mmol/L)	1.17 (0.26)	1.10 (0.28)	1.10 (0.28)	-0.07 (0.23)^*	-0.10 (0.33)^*
PRL (ng/ml)	52.61 (41.35)	119.08 (59.49)	106.83 (60.80)	65.45 (63.01)^**	52.40 (61.57)^**

All the data except ESRS and BAS were shown in mean (standard deviation) form
ESRS Extrapyramidal Symptom Rating Scale, BAS Barnes Akathisia Scale, BMI body mass index, Glu fasting glucose, TG triglyceride, CHO cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, PRL prolactin
^*p < 0.05
^**p < 0.01

ISSN: 1471-244X